EP0000071B1 - Stabilised thymidine phosphorylase preparation and culture medium containing it - Google Patents
Stabilised thymidine phosphorylase preparation and culture medium containing it Download PDFInfo
- Publication number
- EP0000071B1 EP0000071B1 EP78100132A EP78100132A EP0000071B1 EP 0000071 B1 EP0000071 B1 EP 0000071B1 EP 78100132 A EP78100132 A EP 78100132A EP 78100132 A EP78100132 A EP 78100132A EP 0000071 B1 EP0000071 B1 EP 0000071B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- preparation
- thymidine phosphorylase
- enzyme
- stabilised
- thymidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1077—Pentosyltransferases (2.4.2)
Definitions
- This invention relates to a preparation of thymidine phosphorylase for incorporation into culture media used for the testing of the susceptibility of bacteria to antifolate anti-microbial agents such as sulphamethoxazole (SMX) and/or trimethoprim (TMP), in particular it relates to an improved stabilised thymidine phosphorylase preparation and a culture medium containing it.
- SMX sulphamethoxazole
- TMP trimethoprim
- thymidine At very high levels of thymidine, that is greater than about 15 ,ug/ml, the activity of the Harper-Cawston Factor is not sufficient to overcome the reversal of the activities of the sulphonamides and trimethoprim, possibly because the high concentration of thymine produced as a result of the cleavage of thymidine, can replace the much more active thymidine in the reversal.
- the Harper-Cawston Factor has been reported to be thymidine phosphorylase (Bushby in Trimethoprim/Sulphamethoxazole in Bacterial Infections: A Wellcome Foundation Symposium Ed. Bernstein Et Salter, Churchill Livingston, Edinburgh Et London, 1973, 1, 10-18; Ferone et al, Antimicrobial Agents and Chemotherapy, (1975), 7, 91). It has been pointed out in the former reference that "although thymidine interferes with the in vitro activity of trimethoprim/sulphamethoxazole, it is not usually present in animals in sufficiently high concentrations to affect the in vivo activity.”
- thymidine phosphorylase purified from Escherichia coli suggested that under certain conditions thymine, phosphate, and thymidine phosphorylase may form a dead-end complex, that is a complex which is itself not catalytically active but the formation of which must be reversed before the enzyme can form catalytically active complexes. This finding suggested that the dead-end complex might be more stable than the free enzyme. Since thymine is an undesirable additive to the media; as hereinabove explained, a substitute for this was looked for.
- a stabilised thymidine phosphorylase preparation containing uracil and inorganic phosphate.
- the thymidine phosphorylase for use in the present invention may be obtained by purification from a number of bacteria such as Salmonella typhimurium, Bacillus cereus, Bacillus stearothermophilus, Haemophilus influenzae and particularly from a strain of Escherichia coli requiring thymine and methionine for growth.
- the purification may be carried out by the method described by Schwartz, Eur., J. Biochem., (1971), 21, 191-198, which method involves a somewhat lengthy process of precipitation, fractionation, chromatography and dialysis.
- a more preferred process is that described in Belgian Patent No. 837 946 and published German Patent application No. P 26 02 996.9 which disclose that a certain strain of E.
- coli. produces inordinate amounts of thymidine phosphorylase under appropriate growth conditions and that it may be isolated and purified by applying the cell extract to specific adsorbents and eluting it therefrom, to give a much higher yield and purity than the method of Schwartz.
- Monitoring of the eluates at all stages of the purification process employed may be carried out using a spectrophotometric assay at a selected wavelength in order to ascertain enzyme activity which is expressed in International Units (l.U.), one International Unit being equivalent to that amount of enzyme that will phosphorylise one micromole of thymidine to thymine under the assay conditions used (see Example 1). The peaks that show the highest concentration and purity are selected.
- the enzyme so purified as above is then made available, as previously stated, in a stable form by addition of a combination of uracil and inorganic phosphate.
- a combination of uracil and inorganic phosphate can be used, potassium or ammonium phosphate are preferred.
- the concentration of thymidine phosphorylase incorporated into the media is preferably in the range of about 0.01 to 1,000 International Units/ml and more preferably between 0.02 to 10 International Units/ml.
- the useful concentration limits for uracil and phosphate to produce a stabilised thymidine phosphorylase preparation are 0.5 mM to saturation, preferably 1 to 20 mM, for uracil, and 0.1 mM to saturation, preferably 0.1 to 1.0 M for the inorganic phosphate.
- the serum albumin is preferably added at a concentration of 0.2 to 5% w/v.
- the sterility of the above described formulctions is of great importance in view of their applicaticn to the testing of the sensitivities of bacteria to antifolates. It is often desirable, therefore, to add an antimicrobial agent to the formulation in order to ensure sterility. It is important however that the antimicrobials employed are able to sterilise the formulation without affecting the enzyme stability. It has been found that alkali metal azides such as sodium azide or potassium azide are excellent antimicrobials for the purposes of the present invention since they do not interfere with enzyme activity and in the use of the formulations of the present invention are diluted out to ineffectiveness as antimicrobial agents.
- the antimicrobial agent as hereinabove defined, may be incorporated into the preparation at a concentration of 0.001 to 0.4% w/v, preferably 0.002 to 0.2% w/v.
- uracil alone or potassium phosphate alone are not as effective in stabilising the enzyme as is their combination. Furthermore, this combination is much more effective with low concentrations of enzyme than is the formulation used in Example 1.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB2466577 | 1977-06-14 | ||
GB2466577 | 1977-06-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0000071A1 EP0000071A1 (en) | 1978-12-20 |
EP0000071B1 true EP0000071B1 (en) | 1981-08-05 |
Family
ID=10215321
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP78100132A Expired EP0000071B1 (en) | 1977-06-14 | 1978-06-09 | Stabilised thymidine phosphorylase preparation and culture medium containing it |
Country Status (13)
Country | Link |
---|---|
US (1) | US4219621A (ja) |
EP (1) | EP0000071B1 (ja) |
JP (1) | JPS548791A (ja) |
AU (1) | AU516545B2 (ja) |
CA (1) | CA1112193A (ja) |
DE (1) | DE2860890D1 (ja) |
DK (1) | DK264878A (ja) |
ES (1) | ES470728A1 (ja) |
FI (1) | FI60031C (ja) |
HU (1) | HU179360B (ja) |
IL (1) | IL54898A (ja) |
IT (1) | IT1106103B (ja) |
ZA (1) | ZA783394B (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ251094A3 (en) * | 1993-02-11 | 1995-02-15 | Gist Brocades Nv | Unit for detecting residues of antibacterial substances in liquids |
JP2011136911A (ja) * | 2009-12-25 | 2011-07-14 | Tosoh Corp | 甲状腺刺激ホルモンレセプターの安定化方法 |
CN103305487B (zh) * | 2012-11-20 | 2014-11-05 | 上海理工大学 | 一种利用短乳杆菌发酵生产胸苷磷酸化酶的方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1513461A (en) * | 1975-01-27 | 1978-06-07 | Wellcome Found | Bacterial culture medium |
-
1978
- 1978-06-09 EP EP78100132A patent/EP0000071B1/en not_active Expired
- 1978-06-09 DE DE7878100132T patent/DE2860890D1/de not_active Expired
- 1978-06-13 DK DK264878A patent/DK264878A/da not_active Application Discontinuation
- 1978-06-13 AU AU37061/78A patent/AU516545B2/en not_active Expired
- 1978-06-13 JP JP7142278A patent/JPS548791A/ja active Granted
- 1978-06-13 CA CA305,302A patent/CA1112193A/en not_active Expired
- 1978-06-13 IT IT49852/78A patent/IT1106103B/it active
- 1978-06-13 HU HU78WE578A patent/HU179360B/hu unknown
- 1978-06-13 US US05/915,153 patent/US4219621A/en not_active Expired - Lifetime
- 1978-06-13 ZA ZA783394A patent/ZA783394B/xx unknown
- 1978-06-13 ES ES470728A patent/ES470728A1/es not_active Expired
- 1978-06-13 FI FI781887A patent/FI60031C/fi not_active IP Right Cessation
- 1978-06-13 IL IL54898A patent/IL54898A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
AU3706178A (en) | 1979-12-20 |
ES470728A1 (es) | 1979-02-01 |
FI781887A (fi) | 1978-12-15 |
CA1112193A (en) | 1981-11-10 |
IL54898A (en) | 1981-03-31 |
US4219621A (en) | 1980-08-26 |
ZA783394B (en) | 1980-02-27 |
IL54898A0 (en) | 1978-08-31 |
IT7849852A0 (it) | 1978-06-13 |
HU179360B (en) | 1982-10-28 |
DK264878A (da) | 1978-12-15 |
JPS548791A (en) | 1979-01-23 |
EP0000071A1 (en) | 1978-12-20 |
AU516545B2 (en) | 1981-06-11 |
IT1106103B (it) | 1985-11-11 |
JPS6156998B2 (ja) | 1986-12-04 |
DE2860890D1 (en) | 1981-11-05 |
FI60031C (fi) | 1981-11-10 |
FI60031B (fi) | 1981-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Roberts et al. | Isolation, crystallization, and properties of Achromobacteraceae glutaminase-asparaginase with antitumor activity | |
Takaku et al. | In vivo anti‐tumor activity of arginine deiminase purified from Mycoplasma arginini | |
Andrews | Purification of lactose synthetase a protein from human milk and demonstration of its interaction with α‐lactalbumin | |
WO1992002133A1 (en) | Improved diagnostic and therapeutic compositions | |
Ferone et al. | Identification of Harper-Cawston factor as thymidine phosphorylase and removal from media of substances interfering with susceptibility testing to sulfonamides and diaminopyrimidines | |
Sarkar et al. | Isolation and characterization of glutamine synthetase from chicken neural retina | |
US3855142A (en) | Enzymatic denture cleanser | |
Lehrer et al. | Increased content of microbicidal cationic peptides in rabbit alveolar macrophages elicited by complete Freund adjuvant | |
EP0000071B1 (en) | Stabilised thymidine phosphorylase preparation and culture medium containing it | |
Morehouse et al. | Properties of rat renal phosphate-dependent glutaminase coupled to Sepharose. Evidence that dimerization is essential for activation | |
Okuda et al. | Inhibitory effects of ciprofloxacin and sparfloxacin on DNA gyrase purified from fluoroquinolone-resistant strains of methicillin-resistant Staphylococcus aureus | |
US4366249A (en) | Storage stable cholesterol oxidase compositions | |
Wriston Jr | 5 L-Asparaginase | |
CA1077379A (en) | Bacterial culture medium | |
US5658948A (en) | Enhancement of benzalkonium chloride preservative activity in formulations containing an incompatible drug using amino acids having net positive charge | |
León et al. | Fosfomycin resistance plasmids do not affect fosfomycin transport into Escherichia coli | |
Boxer et al. | Leukocyte disorders: quantitative and qualitative disorders of the neutrophil, Part 2 | |
Feder et al. | Stabilization of proteolytic enzymes in solution | |
Formica et al. | Production, isolation, and properties of azetomycins | |
JP2002255988A5 (ja) | ||
EP0065800B1 (en) | Enzyme solutions and method for the preparation thereof | |
US4178212A (en) | Stabilized thymidine phosphorylase formulation | |
EP1735437B1 (en) | Highly purified proteinase k | |
CA1077420A (en) | Stabilized preparation of thymidine phosphorylase | |
McFeters et al. | Involvement of Sulfhydryl Groups in the β-Galactosidase of Streptococcus lactis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): BE CH DE FR GB NL SE |
|
17P | Request for examination filed | ||
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): BE CH DE FR GB NL SE Designated state(s): BE CH DE FR GB NL SE |
|
REF | Corresponds to: |
Ref document number: 2860890 Country of ref document: DE Date of ref document: 19811105 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 19840319 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 19840321 Year of fee payment: 7 Ref country code: DE Payment date: 19840321 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 19840331 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 19840630 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 19850630 Year of fee payment: 8 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Effective date: 19860630 |
|
BERE | Be: lapsed |
Owner name: THE WELLCOME FOUNDATION LTD Effective date: 19860630 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Effective date: 19870101 |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Effective date: 19880609 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Effective date: 19880610 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Effective date: 19880630 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 19890228 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Effective date: 19890301 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |
|
EUG | Se: european patent has lapsed |
Ref document number: 78100132.6 Effective date: 19890220 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |